echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Junshi Bio's PD-1 inhibitor first-line treatment of non-small cell lung cancer is accepted by CDE

    Junshi Bio's PD-1 inhibitor first-line treatment of non-small cell lung cancer is accepted by CDE

    • Last Update: 2022-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Transfer from | Pharmaceutical Mission Hills

    On December 10th, Junshi Biotech announced that the National Medical Products Administration (NMPA) of China has accepted its self-developed anti-PD-1 monoclonal antibody drug teriprizumab combined with standard first-line chemotherapy for untreated, driver genes A new indication for the marketing of negative advanced non-small cell lung cancer (NSCLC) is the sixth listing application submitted by Teriplizumab in China


    The marketing application for this new indication is based on the CHOICE-01 study (NCT03856411).


    The study enrolled a total of 465 NSCLC patients in 63 centers across the country, including 220 squamous cancer subjects and 245 non-squamous cancer subjects.


    According to the results of the interim analysis of the CHOICE-01 study, the Independent Data Monitoring Committee (IDMC) determined that its main research endpoint, Progression-Free Survival (PFS), reached the superiority threshold preset by the protocol


    Junshi Biotech stated that it will subsequently submit further analysis results of the CHOICE-01 study OS to regulatory agencies and communicate with the US FDA about the submission of the listing application


    Lung cancer is currently the world's second most common malignant tumor with the second highest mortality rate


    Original title: For the first-line treatment of non-small cell lung cancer, Junshi Biologics submits a new indication for PD-1 inhibitor listing application!

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.